Cargando…
Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
Evidence from rodent and in vitro models suggests that activation of PPAR-γ by thiazolidinediones (TZDs) causes increased bone marrow adiposity and decreased osteoblastogenesis, resulting in bone loss. TZDs are prescribed for the treatment of diabetes, providing an opportunity to determine whether P...
Autor principal: | Schwartz, Ann V. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779575/ https://www.ncbi.nlm.nih.gov/pubmed/17259663 http://dx.doi.org/10.1155/PPAR/2006/24502 |
Ejemplares similares
-
TZDs and Bone: A Review of the Recent Clinical Evidence
por: Schwartz, Ann V.
Publicado: (2008) -
What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin?
por: Curtiss, Frederic R.
Publicado: (2006) -
Thiazolidinediones (TZDs) enhance insulin secretory response via GPR40 and adenylate cyclase (AC)
por: Hwang, Mina, et al.
Publicado: (2021) -
PPARγ activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFβ signalling
por: Jarrar, Mohammed H, et al.
Publicado: (2007) -
Marrow Fat and Bone: Review of Clinical Findings
por: Schwartz, Ann V.
Publicado: (2015)